Literature DB >> 8039248

Requirement for protein synthesis in antigen processing by B cells.

K M Soreng1, J C Moore, M A Sherman, P E Jensen.   

Abstract

The role de novo protein synthesis plays in Ag processing by B cells was investigated. Cycloheximide (CHX) inhibited Ag processing in normal and transformed B cells. B lymphoblastoid cells required a 2-6 hr longer CHX pretreatment period than splenic B cells to inhibit Ag processing function. Immunoprecipitation experiments demonstrated that the half-life of class II/invariant chain (Ii) complexes was similar in normal and transformed B cells. B lymphoblastoid cells differed from splenic B cells in that a significant fraction of total class II-associated p31 Ii was modified with sialic acid (Ip). The kinetics of loss of class II-associated Ip in CHX-treated cells correlated with loss of Ag processing function. In addition, the half-life of a subpopulation of class II molecules that are unstable in sodium dodecyl sulfate at room temperature was greater in transformed cells. Our results suggest that B lymphoblastoid cells, but not splenic B cells, contain a long-lived pool of class II/Ii complexes that can bind and present peptides generated in endosomal compartments for a significant time period after cessation of protein synthesis.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8039248     DOI: 10.1006/cimm.1994.1222

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  3 in total

1.  Purification of intracellular compartments involved in antigen processing: a new method based on magnetic sorting.

Authors:  L A Perrin-Cocon; P N Marche; C L Villiers
Journal:  Biochem J       Date:  1999-02-15       Impact factor: 3.857

2.  Diminished intracellular invariant chain expression after vaccinia virus infection.

Authors:  Nan Wang; Ekkehard Weber; Janice S Blum
Journal:  J Immunol       Date:  2009-07-10       Impact factor: 5.422

3.  Delivery of B cell receptor-internalized antigen to endosomes and class II vesicles.

Authors:  J R Drake; P Webster; J C Cambier; I Mellman
Journal:  J Exp Med       Date:  1997-10-20       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.